RICTOR

Across TCGA pan-cancer cohorts, RICTOR mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RICTOR data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RICTOR mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RICTOR expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where RICTOR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.417	0.625	.006	29	view →
CCRCC	OS	Median	All	0.740	1.000	.021	11	view →
LSCC	DFS	Tertile	All	0.579	0.841	.007	10	view →
LUAD	OS	Tertile	III,IV	0.879	0.495	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RICTOR–PDAC (OS)

Open the PDAC breakdown →